Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 63 results:
[ Συντάκτης(Desc)] Τίτλος Τύπος Έτος
Φίλτρα: Συντάκτης is Zarogoulidis, Paul  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Z
Zarogoulidis, P., Trakada G., & Zarogoulidis K. (2013).  A chrono-target chemotherapy treatment model for lung cancer treatment.. Ther Deliv. 4(1), 5-8.
Zarogoulidis, P., Huang H., Tsiouda T., Sardeli C., Trakada G., Veletza L., et al. (2017).  Immunotherapy "Shock" with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma.. Respir Med Case Rep. 22, 283-286.
Zarogoulidis, P., Pataka A., Terzi E., Hohenforst-Schmidt W., Machairiotis N., Huang H., et al. (2013).  Intensive care unit and lung cancer: when should we intubate?. J Thorac Dis. 5 Suppl 4, S407-12.
Zarogoulidis, P., Hohenforst-Schmidt W., Huang H., Sapalidis K., Kosmidis C., Tryfon S., et al. (2020).  Vapor for lung volume reduction; pros and cons.. Expert Rev Respir Med. 14(12), 1189-1195.
Zarogoulidis, P., Tsakiridis K., Kioumis I., & Zarogoulidis K. (2014).  Cardiothoracic diseases: basic treatment.. J Thorac Dis. 6 Suppl 1, S1.
Zarogoulidis, P., Draba V., Machairiotis N., Manika K., Mikroulis D., Tsakiridis K., et al. (2012).  Fibrinous tumor of the pleura: an orphan disease lost in translation.. J Thorac Dis. 4(5), 497-503.
Zarogoulidis, P., Glaros D., Kontakiotis T., Froudarakis M., Kioumis I., Kouroumichakis I., et al. (2012).  Health costs from hospitalization with H1N1 infection during the 2009-2010 influenza pandemic compared with non-H1N1 respiratory infections.. Int J Gen Med. 5, 175-82.
Zarogoulidis, P., Petanidis S., Kioseoglou E., Domvri K., Anestakis D., & Zarogoulidis K. (2015).  MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells.. Cell Signal. 27(8), 1576-88.
Zarogoulidis, P., Darwiche K., Hohenforst-Schmidt W., Huang H., Li Q., Freitag L., et al. (2013).  Inhaled gene therapy in lung cancer: proof-of-concept for nano-oncology and nanobiotechnology in the management of lung cancer.. Future Oncol. 9(8), 1171-94.
Zarogoulidis, P., Papadopoulos V., Maragouli E., Papatsibas G., Karapantzos I., Bai C., et al. (2018).  Tumor heterogenicity: multiple needle biopsies from different lesion sites-key to successful targeted therapy and immunotherapy.. Transl Lung Cancer Res. 7(Suppl 1), S46-S48.
Zarogoulidis, P., Darwiche K., Sakkas A., Yarmus L., Huang H., Li Q., et al. (2013).  Suicide Gene Therapy for Cancer - Current Strategies.. J Genet Syndr Gene Ther. 4,
Zarogoulidis, P., Sardeli C., Konstantinou F., & Sapalidis K. (2018).  Conventional Versus Therapeutic Stents for Airway Malignancies: Novel Local Therapies Underway.. EBioMedicine. 33, 10-11.
Zarogoulidis, P., Alexandropoulou I., Romanidou G., Konstasntinidis T. G., Terzi E., Saridou S., et al. (2011).  Community-acquired pneumonia due to Legionella pneumophila, the utility of PCR, and a review of the antibiotics used.. Int J Gen Med. 4, 15-9.
Zarogoulidis, P., Lampaki S., J Turner F., Huang H., Kakolyris S., Syrigos K., et al. (2014).  mTOR pathway: A current, up-to-date mini-review (Review).. Oncol Lett. 8(6), 2367-2370.
Zarogoulidis, P., Kontakiotis T., & Zarogoulidis K. (2012).  Inhaled gene therapy in lung cancer: "as for the future, our task is not to foresee it, but to enable it".. Ther Deliv. 3(8), 919-21.
Zarogoulidis, P., Athanasiou E., Tsiouda T., Hatzibougias D., Huang H., Bai C., et al. (2017).  Immunotherapy "Shock" a case series of PD-L1 100% and pembrolizumab first-line treatment.. Respir Med Case Rep. 22, 197-202.
Zarogoulidis, P., Yarmus L., Darwiche K., Walter R., Huang H., Li Z., et al. (2013).  Interleukin-6 cytokine: a multifunctional glycoprotein for cancer.. Immunome Res. 9(62), 16535.
Zarogoulidis, P., Petridis D., Sapalidis K., Tsakiridis K., Baka S., Vagionas A., et al. (2020).  Lung cancer biopsies: Comparison between simple 22G, 22G upgraded and 21G needle for EBUS-TBNA.. J Cancer. 11(21), 6454-6459.
Zarogoulidis, P., Katsikogianni F., Tsiouda T., Sakkas A., Katsikogiannis N., & Zarogoulidis K. (2014).  Interleukin-8 and interleukin-17 for cancer.. Cancer Invest. 32(5), 197-205.
Zarogoulidis, P., Christakidis V., Petridis D., Sapalidis K., Kosmidis C., Vagionas A., et al. (2020).  Connection between PD-L1 expression and standardized uptake value in NSCLC: an early prognostic treatment combination.. Expert Rev Respir Med.
Zarogoulidis, P., Porpodis K., Konoglou M., Saroglou M., Mitrakas A., Matthaios D., et al. (2011).  Serratia pneumonia presenting as hemoptysis in a patient with sarcoidosis: a case report.. Int J Gen Med. 4, 661-4.
Zarogoulidis, P., Tsakiridis K., Karapantzou C., Lampaki S., Kioumis I., Pitsiou G., et al. (2015).  Use of proteins as biomarkers and their role in carcinogenesis.. J Cancer. 6(1), 9-18.
Zarogoulidis, P., Kioumis I., Ritzoulis C., Petridis D., Darwiche K., Porpodis K., et al. (2013).  New insights in the production of aerosol antibiotics. Evaluation of the optimal aerosol production system for ampicillin-sulbactam, meropenem, ceftazidime, cefepime and piperacillin-tazobactam.. Int J Pharm. 455(1-2), 182-8.
Zarogoulidis, P., Papadopoulos V., Maragouli E., Papatsibas G., Sardeli C., Man Y-G., et al. (2018).  Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ≥50.. Transl Lung Cancer Res. 7(Suppl 1), S28-S30.
Zarogoulidis, P., Petridis D., Ritzoulis C., Li Q., Huang H., Ning Y., et al. (2013).  Further experimentation of inhaled; LANTUS, ACTRAPID and HUMULIN with todays' production systems.. Int J Pharm. 458(1), 39-47.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές